<DOC>
	<DOCNO>NCT02467673</DOCNO>
	<brief_summary>The study aim ass effect micronized ( MIC ) nanoparticulate ( NANO ) transdermal hormone therapy ( THT ) blood pressure , ultra-sensitive C-reactive protein ( CRP ) , cardiovascular risk factor postmenopausal woman .</brief_summary>
	<brief_title>Nanoparticulate Versus Micronized Steroids Delivery Transdermal Hormone Replacement Therapy</brief_title>
	<detailed_description>In open label study , 27 postmenopausal woman , clinical evidence cardiovascular disease , randomly divide two group . During 12 week , 15 patient receive left forearm micronized ( MIC ) THT ( micronized 17β-estradiol 2.5 mg/day + progesterone 100 mg/day ) . 14 patient receive nanoparticulate ( NANO ) THT ( nanoparticulate 17β-estradiol 2.5 mg/day + progesterone 100mg/day ) . After 12 week treatment patient evaluate . Baseline Post-THT measure determine : Insulin , body mass index , waist circumference , blood pressure , CRP-stratified level , total testosterone , TSH FSH level .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>A body mass index 18 27 kg/m2 ; Sex live complaint ; No evidence cardiovascular disease ; General good health base history physical examination . A past history neurological disorder ; Had receive pharmacotherapy cardiovascular disease screen Taking medication know interfere steroid ; Recent psychiatric systemic illness ; Uncontrolled hypertension ( blood pressure &gt; 160/95mmHg ) , Unstable cardiovascular disease ; Genital bleeding ; Use psychoactive medication , Alcohol excess consumption drug abuse ;</criteria>
	<gender>Female</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>